A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma

Summary

COL-3 may stop the growth of cancer by stopping blood flow to the tumor. Randomized phase II trial to compare the effectiveness of two different regimens of COL-3 in treating patients who have HIV-related Kaposi's sarcoma.

Timeline

Start

2003-03

Primary completion

2005-11

Completion

2009-11

Outcome

Outcome not reported

Stopped: “Cancer Therapy Evaluation Program's (CTEP's) termination of drug supply”

Drugs

Indications